Addressing development of treatments for various neurological disorders and move them toward clinical trials and eventual commercialization, Expesicor Inc. is working with the University of Montana. With candidate treatments in the pipeline at various stages of development. the research effort is addressing Alzheimerâs, epilepsy, ALS and traumatic brain injury to include better ways both to detect and to understand such disorders. The firm has developed a drug (EXP-1602) that has cleared by the Food and Drug Administration to begin clinical trials. Expesicor is also working on further develop an imaging agent to identify pain in a patient, specifically using an imaging agent designed to visualize where an individual is experiencing pain providing a more objective pain measurement tool
